Sun Pharma Advanced Research Company Limited reported a financial turnaround for the year ended March 31, 2026, swinging from a loss to a profit on both standalone and consolidated bases. The Board of Directors, at its meeting held on May 18, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The statutory auditors, S R B C & C O L L P, issued an unmodified opinion on the financial results.

Priority Review Voucher Drives Revenue

The defining event of FY26 was the recognition of income of ₹1,84,002 lakhs as other operating revenue regarding a Priority Review Voucher (PRV) granted by the United States Food and Drug Administration (USFDA) on February 03, 2026, for Sezaby®. The PRV, a transferable instrument, was subsequently sold on April 30, 2026, for USD 195 million. The PRV has been accounted for as a non-monetary government grant under Ind AS 20, and its fair value has been recognised in the Statement of Profit and Loss. This single item was instrumental in transforming the company's financial profile for the year.

Standalone Financial Performance

The standalone financial results reflect a sharp reversal from the prior year's losses. The following table summarises the key standalone income statement metrics:

Total standalone expenses for FY26 declined to ₹32,551 lakhs from ₹41,878 lakhs in FY25, reflecting lower clinical trial expenses (₹2,266 lakhs vs ₹8,133 lakhs) and professional charges (₹8,753 lakhs vs ₹14,126 lakhs). An exceptional item of ₹1,236 lakhs was recognised during the quarter ended December 31, 2025, relating to incremental costs arising from the implementation of the New Labour Codes effective November 21, 2025.

Standalone Balance Sheet Highlights

The standalone balance sheet as at March 31, 2026 reflects a significant improvement in the equity position, driven by the year's profitability.

Other current assets surged to ₹1,84,575 lakhs as at March 31, 2026 from ₹550 lakhs a year earlier, primarily reflecting the PRV-related receivable. Total equity turned strongly positive at ₹1,33,358 lakhs compared to a negative ₹22,062 lakhs as at March 31, 2025.

Consolidated Financial Performance

The consolidated results encompass Sun Pharma Advanced Research Company Limited and its wholly owned subsidiaries, SPARCLIFE, Inc. and Genokine Biotech Limited. The consolidated performance closely mirrors the standalone results given the minimal contribution from subsidiaries.

Consolidated total assets stood at ₹2,17,086 lakhs as at March 31, 2026, compared to ₹33,553 lakhs a year earlier. Total consolidated equity improved to ₹1,33,882 lakhs from a negative ₹21,695 lakhs. The Group's only reportable business segment is 'Pharmaceutical Research and Development'.

Cash Flow Overview

On a standalone basis, net cash used in operating activities was ₹23,889 lakhs for FY26, compared to ₹36,241 lakhs in FY25. Net cash used in investing activities was ₹2,351 lakhs, while net cash generated from financing activities was ₹26,153 lakhs, with proceeds from borrowings of ₹2,11,581 lakhs and repayments of ₹1,81,785 lakhs. Standalone cash and cash equivalents at the end of the year stood at ₹32 lakhs. On a consolidated basis, cash and cash equivalents at the end of the year were ₹116 lakhs, compared to ₹196 lakhs at the beginning of the year.

OcuVex Therapeutics, a partner of sun pharma advanced research co , has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for its New Drug Application (NDA) for PDP-716. The CRL was issued in connection with manufacturing inspection issues identified during the regulatory review process.

FDA Issues Complete Response Letter for PDP-716

A Complete Response Letter is issued by the FDA when it determines that a submitted NDA cannot be approved in its present form. The letter communicates the specific deficiencies that the applicant must resolve before the application can be reconsidered for approval. In this instance, the FDA's concerns are linked to manufacturing inspection issues, which form a critical component of the drug approval process.

Implications of the Complete Response Letter

The receipt of a CRL represents a regulatory setback for OcuVex Therapeutics and its partner, Sun Pharma Advanced Research Co, as it delays the potential approval and commercialization of PDP-716. The applicant will be required to address the manufacturing-related deficiencies cited by the FDA before resubmitting the NDA for further review. The timeline for resolution and resubmission will depend on the nature and extent of the manufacturing inspection issues identified by the regulatory authority.